Current issue #25, 2016

Independent pharmacies yield to price competition

The decreasing number of independent pharmacies worries both the distributors and professional organizations. Experts are sure that such trend may negatively affect the pharmaceutical market as a whole. The competition may become less fierce that will have an effect both on the product range and prices; as to the distributors, they will lose the most reliable customers. At the same time, figures testify to an opposite trend: according to AlphaRM, the number of independent pharmacies increased by more than a thousand over the last year, whereas earnings per pharmacy have shrunk dramatically.

[PharmVestnik # 25, 16/08/2016, p. 1, cont’d p. 4]

GMP inspectors reveal non-conformity of drug master files and real manufacture

One of the most frequent questions that pharma companies ask addressing to the GMP Inspectorate and the Ministry of Industry and Trade is as follows: What will happen if GMP inspectors reveal non-conformity of the master file data for the drugs imported to Russia and real-life manufacturing processes? Representatives of some businesses are sure that the final expert reports should not reflect such discrepancies. Judging by their active stand when supporting their viewpoints at the workshop that was hosted by the State Institute of Medicinal Products and Good Practices in late July, such cases are far from being occasional.

[PharmVestnik # 25, 16/08/2016, p. 2]

Local vaccines

The government to discuss a list of drugs subject to complete localization

The Ministry of Health continues working on a list of immunobiologicals to be manufactured in Russia based on a full cycle. To the knowledge of PharmVestnik, on August 5, a draft list was submitted to the Russian Government Expert Council.

[PharmVestnik # 25, 16/08/2016, p. 3]

Manufacturing costs of pharma companies to be checked

President V. Putin entrusted the Federal Antimonopoly Service with checking feasibility of Russian drug manufacturers’ costs proceeding from the world raw material and API prices. Experts have a positive attitude towards such action, but they do not hope that the state price regulation situation may resolve soon.

[PharmVestnik # 25, 16/08/2016, p. 4]

Diseases untypical for Russia driv...